Share
Steve Sandweg
Valcare Medical, Inc., a pioneer in transcatheter-based mitral solutions, has announced a major corporate restructuring led by TechWald Next to fast-track clinical trials for it’s AMEND mitral annuloplasty device in Europe and the U.S. As part of this restructuring, TechWald has appointed Steve Sandweg as the new Chief Executive Officer.
Sandweg brings over 25 years of experience in the medical device industry, having held leadership roles at major companies, including EBR Systems, Keystone Heart, and Medtronic. At Medtronic, he played a critical role in launching innovative cardiovascular products like the CoreValve/EVOLUT and drug-eluting stents. Sandweg expressed his excitement about joining Valcare Medical, emphasizing the restructuring as an opportunity to accelerate the company’s growth and the launch of the AMEND Plus European pilot study.
Along with the new CEO, Valcare appointed a new Board of Directors chaired by Chris Richardson, who has over 30 years of experience in guiding medtech startups through clinical trials, regulatory approval, and acquisitions. Richardson praised Sandweg’s appointment, highlighting his operational expertise and leadership as key to executing Valcare’s vision to improve care for patients suffering from severe mitral regurgitation.
Valcare’s AMEND device, a clinically proven D-shaped mitral valve repair solution, serves as the foundation for the company’s future developments in mitral replacement and tricuspid repair solutions.
Related posts
.jpg "Integra LifeSciences Appoints Dr. Raymond Turner as Chief Medical Officer")
